These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 33318014)
1. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Eke AC; Shoji K; Best BM; Momper JD; Stek AM; Cressey TR; Mirochnick M; Capparelli EV Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318014 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tenofovir during pregnancy and postpartum. Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M; HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631 [TBL] [Abstract][Full Text] [Related]
3. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR; J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984 [TBL] [Abstract][Full Text] [Related]
4. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Acosta EP; Mager DE; Morse GD; Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642925 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL; Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112 [TBL] [Abstract][Full Text] [Related]
6. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690 [TBL] [Abstract][Full Text] [Related]
7. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review. Wu L; Niu X; Brunelli MK; Mugwanya KK Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667 [TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Baheti G; Kiser JJ; Havens PL; Fletcher CV Antimicrob Agents Chemother; 2011 Nov; 55(11):5294-9. PubMed ID: 21896913 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M; Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. Bierhoff M; Smolders EJ; Tarning J; Burger DM; Spijker R; Rijken MJ; Angkurawaranon C; McGready R; White NJ; Nosten F; van Vugt M Antivir Ther; 2019; 24(7):529-540. PubMed ID: 31868655 [TBL] [Abstract][Full Text] [Related]
11. Development of normal reference intervals for renal function in pregnancy: a secondary analysis of clinical trial data. Legoabe Z; Sebitloane M; Lombard C; Naidoo M; Gray G; Moodley D J Obstet Gynaecol; 2024 Dec; 44(1):2361445. PubMed ID: 38832538 [TBL] [Abstract][Full Text] [Related]
12. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689 [TBL] [Abstract][Full Text] [Related]
13. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240 [TBL] [Abstract][Full Text] [Related]
14. Do Chinese HIV-infected adult patients with altered renal function need to adjust tenofovir disoproxil fumarate dosage? A population pharmacokinetics analysis. Chen R; Zhang RF; Xing YR; Wang JR; Liu L; Yin L; Li YY; Jiao Z; Zhang LJ Eur J Pharm Sci; 2024 Oct; 201():106851. PubMed ID: 39009286 [TBL] [Abstract][Full Text] [Related]
15. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial. Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974 [TBL] [Abstract][Full Text] [Related]
19. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350 [TBL] [Abstract][Full Text] [Related]
20. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Baheti G; King JR; Acosta EP; Fletcher CV AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]